

L3 ANSWER 1 OF 1 MEDLINE  
 ACCESSION NUMBER: 1998388326 MEDLINE  
 DOCUMENT NUMBER: 98388326 PubMed ID: 9721431  
 TITLE: **Rapamune** (RAPA, rapamycin, sirolimus): mechanism  
 of action immunosuppressive effect results from blockade  
 of  
 signal transduction and inhibition of cell cycle  
 progression.  
 AUTHOR: Sehgal S N  
 CORPORATE SOURCE: Wyeth-Ayerst Research, Princeton, New Jersey 08543, USA.  
 SOURCE: CLINICAL BIOCHEMISTRY, (1998 Jul) 31  
 (5) 335-40. Ref: 69  
 Journal code: 0133660. ISSN: 0009-9120.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199811  
 ENTRY DATE: Entered STN: 19990106  
 Last Updated on STN: 19990106  
 Entered Medline: 19981109  
 AB OBJECTIVE: Rapamune is a novel immunosuppressive agent in Phase III  
 clinical trial in renal transplantation. Its unique mechanism of action  
 has created great interest in its use as a biochemical probe of signal  
 transduction pathways that has provided insight into its molecular  
 mechanism of action. This article reviews the current state of our  
 understanding of the mechanism of action of rapamune.